Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerance, and PK of Faldaprevir (BI 201335) in Healthy Males
NCT02182271Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2004
- Primary completion
- Oct 2004
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 1, randomised, double-blind trial in hepatitis C (HCV) comparing BI 201335 ZW with Placebo (2 arms). Primary endpoints: Number of patients with abnormal findings in physical examination, Number of patients with clinically significant changes in vital signs and 4 more. Started Oct 2004; status: terminated.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02182271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182271.